Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AURA
SellHot AirAura Biosciences, Inc. · Healthcare · United States · $767M · Avg Vol: $5M/d
COMPANY DESCRIPTION
Aura Biosciences, Inc. is a clinical-stage biotechnology company developing virus-like drug conjugates (VDCs) for the treatment of ocular oncology. Its lead product candidate, belzupacap sarotalocan (AU-011), is being developed for ocular melanoma, a rare and aggressive eye cancer. The company's innovative VDC platform represents a novel approach to targeted cancer therapy, addressing unmet medical needs in underserved indications.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | — | — | — | 4.9M | — |
| EPS | -8.95 | -0.72 | -0.92 | -0.85 | -1.76 | — | -1.73 | -1.67 | -1.52 | — |
| Shares | 29.2M | 103.4M | 103.4M | 103.4M | 63.6M | +117.7% | — | — | — | — |
| Debt | 1.0M | 20.9M | 19.6M | 18.8M | 17.4M | 105.5% | 16.6M | — | — | — |
| Equity | 152.3M | 195.6M | 225.8M | 152.0M | 136.9M | -2.6% | — | — | — | — |
| Op CF | -32.4M | -54.6M | -63.8M | -79.8M | -84.7M | — | -103.0M | — | — | — |
| Inv CF | -2.1M | -67.9M | -114.0M | 68.8M | 35.6M | — | — | — | — | — |
| Fin CF | 166.3M | 95.6M | 97.3M | 1.6M | 77.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AURA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AURA | Aura Biosciences, Inc.(you) | $767M | 23 | Sell |
| NVCT | Nuvectis Pharma, Inc. | $775M | 24 | Sell |
| FDMT | 4D Molecular Therapeutics, Inc. | $810M | 24 | Sell |
| DRUG | Bright Minds Biosciences Inc. | $714M | 22 | Sell |
| ACRS | Aclaris Therapeutics, Inc. | $885M | 24 | Sell |
| CBIO | Crescent Biopharma, Inc. | $659M | 22 | Sell |
| TECX | Tectonic Therapeutic, Inc. | $696M | 21 | Sell |
| VSTM | Verastem, Inc. | $654M | 26 | Sell |
| ACHV | Achieve Life Sciences, Inc. | $834M | 19 | Strong Sell |
| AVTX | Avalo Therapeutics, Inc. | $1.1B | 24 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%